Medtech firm Oxford Endovascular, situated in Oxford, UK, has secured a GBP8 million Series A+ investment round.
Investors
- Parkwalk Advisors
- the University of Oxford
- Vulpes
- Oxford Science Enterprises (OSE)
- Norcliffe Capital.
Use of funds
With the money, the business hopes to further expand operations and get its medical device, OXIFLOW, one step closer to a First-In-Human clinical trial.
About Oxford Endovascular
An Oxford University spin-out led by CEO Mike Karim, aims to treat brain aneurysms, a disorder that affects one in fifty people, in order to prevent brain hemorrhage. The business is developing a new, next-generation flow diverter called OxiFlowTM™️ that redirects blood flow away from cerebral aneurysms that might burst. It reduces the chance of difficulties by placing more safely and correctly than current devices. Because it better fits blood arteries, more people can be treated.
